Keros halts entire Phase 2 PAH trial (all doses, placebo) on pericardial effusion safety

Keros Therapeutics, Inc.

Voluntary halt of all dosing in TROPOS trial, including 1.5 mg/kg and placebo arms, due to new pericardial effusion adverse events.
Previously halted 3.0 mg/kg and 4.5 mg/kg arms on Dec 12, 2024; now entire study terminated early.
Patients to be monitored through end-of-trial visits; investigators and FDA notified.
Company still expects to present topline data from all treatment arms in Q2 2025.
CEO Jasbir Seehra cited patient safety as top priority; working with FDA and other regulators.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.